Regulator of G-protein signalling 5 protects against atherosclerosis in apolipoprotein E-deficient mice

British Journal of Pharmacology

Volumn 172, Issue 23, 2015, Pages 5676-5689

  Cheng, Wen Lin ^a   Wang, Pi Xiao ^b   Wang, Tao ^b   Zhang, Yan ^b   Du, Cheng ^b   Li, Hongliang ^b   Ji, Yong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CD31 ANTIGEN; COLLAGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REGULATOR OF G PROTEIN SIGNALLING 5 PROTEIN; RGS PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; RGS5 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; LIPID DIET; LIPID STORAGE; MACROPHAGE MIGRATION; MALE; MIDDLE AGED; MOUSE; MOUSE MODEL; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; ANIMAL; DEFICIENCY; GENETICS; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; MICE; MICE, KNOCKOUT; RGS PROTEINS;

EID: 84949539703     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12991     Document Type: Article

References (45)

1. Adams LD, Geary RL, McManus B, Schwartz SM, (2000). A comparison of aorta and vena cava medial message expression by cDNA array analysis identifies a set of 68 consistently differentially expressed genes, all in aortic media. Circ Res 87: 623-631.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol, 170: 1797-1867.
3. Anger T, Grebe N, Osinski D, Stelzer N, Carson W, Daniel WG, et al. (2008). Role of endogenous RGS proteins on endothelial ERK 1/2 activation. Exp Mol Pathol 85: 165-173.
4. Bondjers C, Kalen M, Hellstrom M, Scheidl SJ, Abramsson A, Renner O, et al. (2003). Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells. Am J Pathol 162: 721-729.
5. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, et al. (1996). Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 97: 1715-1722.
6. Brown BG, Zhao XQ, Sacco DE, Albers JJ, (1993). Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease. Annu Rev Med 44: 365-376.
7. Cho H, Kozasa T, Bondjers C, Betsholtz C, Kehrl JH, (2003). Pericyte-specific expression of Rgs5: implications for PDGF and EDG receptor signaling during vascular maturation. FASEB J 17: 440-442.
8. Choy JC, Granville DJ, Hunt DW, McManus BM, (2001). Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 33: 1673-1690.
9. Clarke M, Bennett M, (2006). The emerging role of vascular smooth muscle cell apoptosis in atherosclerosis and plaque stability. Am J Nephrol 26: 531-535.
10. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA, (2000). The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 20: E83-E88.
11. Deng W, Wang X, Xiao J, Chen K, Zhou H, Shen D, et al. (2012). Loss of regulator of G protein signaling 5 exacerbates obesity, hepatic steatosis, inflammation and insulin resistance. PLoS ONE 7: e30256.
12. Furuya M, Nishiyama M, Kimura S, Suyama T, Naya Y, Ito H, et al. (2004). Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma. J Pathol 203: 551-558.
13. Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJ, Kardakaris R, et al. (2008). Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab 8: 372-383.
14. Glass CK, Witztum JL, (2001). Atherosclerosis. The road ahead. Cell 104: 503-516.
15. Gu S, Cifelli C, Wang S, Heximer SP, (2009). RGS proteins: identifying new GAPs in the understanding of blood pressure regulation and cardiovascular function. Clin Sci (Lond) 116: 391-399.
16. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, et al. (2008). Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453: 410-414.
17. Harrison DG, (1997). Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100: 2153-2157.
18. Hollinger S, Hepler JR, (2002). Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 54: 527-559.
19. Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD, et al. (1999). Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 85: 199-207.
20. Jiang DS, Wei X, Zhang XF, Liu Y, Zhang Y, Chen K, et al. (2014). IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling. Nat Commun 5: 3303.
21. Jin Y, An X, Ye Z, Cully B, Wu J, Li J, (2009). RGS5, a hypoxia-inducible apoptotic stimulator in endothelial cells. J Biol Chem 284: 23436-23443.
22. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
23. Kirsch T, Wellner M, Luft FC, Haller H, Lippoldt A, (2001). Altered gene expression in cerebral capillaries of stroke-prone spontaneously hypertensive rats. Brain Res 910: 106-115.
24. Kolodgie FD, Virmani R, Burke AP, Farb A, Weber DK, Kutys R, et al. (2004). Pathologic assessment of the vulnerable human coronary plaque. Heart 90: 1385-1391.
25. Kyriakis JM, Avruch J, (2001). Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869.
26. Kyriakis JM, Avruch J, (2012). Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 92: 689-737.
27. Ley K, Laudanna C, Cybulsky MI, Nourshargh S, (2007). Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7: 678-689.
28. Li H, He C, Feng J, Zhang Y, Tang Q, Bian Z, et al. (2010). Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci U S A 107: 13818-13823.
29. Li L, Chen W, Zhu Y, Wang X, Jiang DS, Huang F, et al. (2014). Caspase Recruitment domain 6 protects against cardiac hypertrophy in response to pressure overload. Hypertension 64: 94-102.
30. Libby P, (2002). Inflammation in atherosclerosis. Nature 420: 868-874.
31. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. (2010). Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121: 948-954.
32. Lu J, Bian ZY, Zhang R, Zhang Y, Liu C, Yan L, et al. (2013). Interferon regulatory factor 3 is a negative regulator of pathological cardiac hypertrophy. Basic Res Cardiol 108: 326.
33. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, et al. (1999). Protective role of interleukin-10 in atherosclerosis. Circ Res 85: e17-e24.
34. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
35. Mestas J, Ley K, (2008). Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med 18: 228-232.
36. Molkentin JD, (2004). Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 63: 467-475.
37. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-D1106.
38. Potteaux S, Deleuze V, Merval R, Bureau MF, Esposito B, Scherman D, et al. (2006). In vivo electrotransfer of interleukin-10 cDNA prevents endothelial upregulation of activated NF-kappaB and adhesion molecules following an atherogenic diet. Eur Cytokine Netw 17: 13-18.
39. Rosenfeld ME, Carson KG, Johnson JL, Williams H, Jackson CL, Schwartz SM, (2002). Animal models of spontaneous plaque rupture: the holy grail of experimental atherosclerosis research. Curr Atheroscler Rep 4: 238-242.
40. Ross R, (1999). Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
41. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. (1995). A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 15: 1512-1531.
42. Surapisitchat J, Hoefen RJ, Pi X, Yoshizumi M, Yan C, Berk BC, (2001). Fluid shear stress inhibits TNF-alpha activation of JNK but not ERK1/2 or p38 in human umbilical vein endothelial cells: inhibitory crosstalk among MAPK family members. Proc Natl Acad Sci U S A 98: 6476-6481.
43. Tabas I, (2005). Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 25: 2255-2264.
44. Tabas I, (2010). Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 10: 36-46.
45. Virmani R, Burke AP, Kolodgie FD, Farb A, (2002). Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol 15: 439-446.